Antitumor activity of a ROR1 × CD3 bispecific antibody in non-small cell lung cancer
Authors:
- 25 July 2023
- journal article
- research article
- Published by Elsevier in International Immunopharmacology
- Vol. 123, 110686
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Bispecific antibodies: a mechanistic review of the pipelineNature Reviews Drug Discovery, 2019
- Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibodyProceedings of the National Academy of Sciences, 2019
- Potent and selective antitumor activity of a T cell-engaging bispecific antibody targeting a membrane-proximal epitope of ROR1Proceedings of the National Academy of Sciences, 2018
- Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell KillingCancer Cell, 2017
- Silencing of Receptor Tyrosine Kinase ROR1 Inhibits Tumor-Cell Proliferation via PI3K/AKT/mTOR Signaling Pathway in Lung AdenocarcinomaPLOS ONE, 2015
- IHC Profiler: An Open Source Plugin for the Quantitative Evaluation and Automated Scoring of Immunohistochemistry Images of Human Tissue SamplesPLOS ONE, 2014
- ROR1, an embryonic protein with an emerging role in cancer biologyProtein & Cell, 2014
- Therapeutic Potential and Challenges of Targeting Receptor Tyrosine Kinase ROR1 with Monoclonal Antibodies in B-Cell MalignanciesPLOS ONE, 2011
- Generation and Characterization of a Chimeric Rabbit/Human Fab for Co-Crystallization of HIV-1 RevJournal of Molecular Biology, 2010
- Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigenCancer Immunology, Immunotherapy, 2010